menu
    • menu
    [{"orgOrder":0,"company":"Nido Biosciences","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"NIDO-361","moa":"Androgen receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Nido Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nido Biosciences \/ 5Am Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Nido Biosciences \/ 5Am Ventures"},{"orgOrder":0,"company":"Nido Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NIDO-361","moa":"Androgen receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Nido Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nido Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nido Biosciences \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Nido Biosciences

    Menu

    Nido Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nido Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Nido Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NIDO-361

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nido Biosciences Earns Orphan Drug Status for SMA Clinical Candidate

                            Details : NIDO-361, a novel small molecule in development for the treatment of Spinal and Bulbar Muscular Atrophy (SBMA), also known as Kennedy’s disease.

                            Product Name : NIDO-361

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 22, 2024

                            Lead Product(s) : NIDO-361

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nido Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Nido Biosciences

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NIDO-361

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : 5Am Ventures

                            Deal Size : $109.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Nido Biosciences Emerges as Clinical Stage Company Raising $109 Million to Advance Treatments for Debilitating...

                            Details : The financing will be used to fund the company’s clinical stage candidate, NIDO-361, a novel small molecule that binds to a distinct site on the androgen receptor and corrects transcriptional dysregulation, in development for the treatment of patients ...

                            Product Name : NIDO-361

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 15, 2023

                            Lead Product(s) : NIDO-361

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : 5Am Ventures

                            Deal Size : $109.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth